Among 588 clusterable patients from 850 undergoing gastric bypass or sleeve gastrectomy in Würzburg, those in the cardiometabolic MASLD cluster (n=49; mean HbA1c 8.4) lost 17.9-22.1% of total body weight through follow-up, versus 25.2-29.9% in the liver-specific cluster (n=52). Secondary worsening of type 2 diabetes struck 36% of the cardiometabolic group at 24 months and 37.5% at 60 months, but 0% of the liver-specific group. Liver fibrosis appeared in 65%, 41.4% and 16.4% of the cardiometabolic, liver-specific and control clusters, respectively. Complication rates did not differ.
The finding fits a growing recognition that surgery does not work equally for everyone with obesity-related fatty liver. The cardiometabolic phenotype, marked by established diabetes and high HbA1c, likely reflects longer disease duration and greater beta-cell loss, so poorer glycaemic durability is plausible and consistent with prior work showing that longer diabetes duration predicts lower remission rates. Cluster membership partly tracks baseline diabetes severity, so the clusters may add little beyond HbA1c and diabetes duration, which surgeons already weigh. The design limits confidence: it is retrospective and single-centre, and only 588 of 850 patients qualified for clustering. The cardiometabolic group is small at 49, and surgery type (bypass versus sleeve) was not clearly balanced across clusters. Practically, the data do not argue against surgery for these patients, since even the weakest group lost nearly a fifth of body weight. They argue for earlier surgery, tighter post-operative diabetes surveillance and realistic expectations. Editorially, this is incremental and confirmatory, useful for counselling but not yet a validated decision tool.